Select trials in T-cell ALL
| Target . | Agent . | Clinical trial # . | Phase . | Age (years) . | Disease status . | Results . |
|---|---|---|---|---|---|---|
| N/A | Nelarabine | NCT02619630 | 2 | 18-59 | Newly diagnosed | |
| N/A | Nelarabine | NCT02881086 | 3 | 18-55 | Newly diagnosed | Goekbuget, et al59 |
| CD38 | daratumumab | NCT05289687 | 2 | 18+ | MRD+ CR/CRi | N/A |
| CD3-CD38 | XmAb18968 | NCT05038644 | 1 | 18+ | R/R | Murthy et al60 |
| BCL2/ BCLXL | LP-118 | NCT04771572 | 1 | 13+ | R/R | N/A |
| BCL2 + LCK | Venetoclax-ponatinib | NCT05268003 | 2 | 18+ | R/R | N/A |
| CD7 | WU-CART-007 | NCT04984356 | 1/2 | 12+ | R/R | Ghobadi et al34 |
| Target . | Agent . | Clinical trial # . | Phase . | Age (years) . | Disease status . | Results . |
|---|---|---|---|---|---|---|
| N/A | Nelarabine | NCT02619630 | 2 | 18-59 | Newly diagnosed | |
| N/A | Nelarabine | NCT02881086 | 3 | 18-55 | Newly diagnosed | Goekbuget, et al59 |
| CD38 | daratumumab | NCT05289687 | 2 | 18+ | MRD+ CR/CRi | N/A |
| CD3-CD38 | XmAb18968 | NCT05038644 | 1 | 18+ | R/R | Murthy et al60 |
| BCL2/ BCLXL | LP-118 | NCT04771572 | 1 | 13+ | R/R | N/A |
| BCL2 + LCK | Venetoclax-ponatinib | NCT05268003 | 2 | 18+ | R/R | N/A |
| CD7 | WU-CART-007 | NCT04984356 | 1/2 | 12+ | R/R | Ghobadi et al34 |
LCK, lymphocytic-specific kinase.